2 results
Approved WMOCompleted
The aim of this study is to investigate what proportion of HBeAg negative, inactive carriers of the hepatitis B virus with low (< 20,000 IU/mL) load will lose HBsAg when treated with nucleot(s)ide analogue/Peg-IFN combination therapy.
Approved WMOCompleted
The main purpose of this study is to investigate the effect of ASTX660 on how quickly and to what extent quinidine and fexofenadine are absorbed, distributed, broken down and eliminated from the body. Quinidine and fexofenadine have been chosen…